SCHEMBL283856

SCHEMBL283856

O=S1(=O)CCC(CO)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13224655 1.00
SCHEMBL25176236 0.86 ALDH1A1 (0.42)
SCHEMBL1192172 0.84 ALDH1A1 (0.43)
SCHEMBL5468894 0.81 ALDH1A1 (0.52)
SCHEMBL25018631 0.78
SCHEMBL22674639 0.78 ALDH1A1 (0.53)
SCHEMBL5474905 0.78 ALDH1A1 (0.48)
SCHEMBL31715630 0.76 KDM4E (0.38)
SCHEMBL351595 0.75
SCHEMBL23855184 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103475-A1 MAP4K1 INHIBITORS BLUEPRINT MEDICINES CORP (US) 2026-04-16 US disclosed
EP-4288426-B1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-04 EP disclosed
WO-2025226892-A1 SPIROCYCLE-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS SEPTERNA, INC. (US) 2025-10-30 WO disclosed
US-12202844-B2 MAP4K1 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2025-01-21 US disclosed
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-11-07 US disclosed
US-20240317706-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-26 US disclosed
EP-4370523-A1 HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS Blueprint Medicines Corporation (US) 2024-05-22 EP disclosed
US-20240158392-A1 SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES JANSSEN RESEARCH & DEVELOPMENT, LLC 2024-05-16 US disclosed
CN-117940438-A Heterocyclic compounds as MAP4K1 inhibitors 缆图药品公司 2024-04-26 CN disclosed
EP-4288426-A1 QUINOXALINE DERIVATIVES AND USES THEREOF Black Diamond Therapeutics, Inc. (US) 2023-12-13 EP disclosed
US-7732440-B2 Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals SANOFI-AVENTIS (FR) 2010-06-08 US disclosed
US-7732440-B2 Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals SANOFI-AVENTIS (FR) 2010-06-08 US disclosed
US-7732440-B2 Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals SANOFI-AVENTIS (FR) 2010-06-08 US disclosed
US-20100069348-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
US-20100069349-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
US-20090325942-A1 PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-31 US disclosed
US-20090325942-A1 PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-31 US disclosed
US-20090325942-A1 PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-31 US disclosed
US-20090062531-A1 Arylacetate Derivatives Having Isoxazole Skeleton SHIONOGI & CO., LTD. (JP) 2009-03-05 US disclosed
EP-1887000-A1 ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON Shionogi Co., Ltd. (JP) 2008-02-13 EP disclosed